| abstract |
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3 and have optimized functional properties compared to the anti-LAG-3 antibodies previously described, such as antibody 25F7 (US 2011/0150892 A1). to provide. These properties include reduced deamidation sites, and physical (ie thermal and chemical) stability, while still maintaining high affinity binding to human LAG-3. Also provided are nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods of expressing the antibodies of the invention, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides a method for detecting LAG-3 using the anti-LAG-3 antibody of the present invention, as well as a method for treating, and a method for stimulating an immune response. Combination therapy is also provided in which the antibody is co-administered with at least one additional immunostimulatory antibody. |